Protalix BioTherapeutics, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $191.8M
- Price
- $2.38
- % Change (Daily % change from the live per-ticker quote feed.)
- 0.00%
- Volume
- 648.5K
About
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. The company is headquartered in Hackensack. New Jersey.
Quick stats
Shares outstanding80.6M
Computed float75.0M
Float / shares93.1%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001006281
Websitehttps://www.protalix.com
AI Summary
AI-generated1/10
majorbullishearnings
Protalix BioTherapeutics Reports Second Quarter 2026 Financial and Business Results
Protalix reported Q2 2026 revenue from selling goods of $19.8 million, up from the prior year, with total year-to-date revenue climbing to $53.6 million driven by Elfabrio sales and a $25.0 million milestone payment from Chiesi.
The company achieved year-to-date profitability with a net income of $22.1 million, reversing a net loss of $3.5 million in the same period of 2025.
Management reaffirmed full-year 2026 revenue guidance of $78.0 million to $83.0 million and reported cash, cash equivalents, and short-term deposits of $40.7 million as of June 30, 2026.